What is the current valuation of the US idiopathic pulmonary-fibrosis-treatment market?

The market valuation was $816.9 Million in 2024. Read More

What is the projected market valuation for the US idiopathic pulmonary-fibrosis-treatment market by 2035?

The projected valuation for 2035 is $1672.0 Million. Read More

Which drug class generated the highest revenue in the US idiopathic pulmonary-fibrosis-treatment market?

Antifibrotic agents generated revenue between $300.0 Million and $600.0 Million. Read More

What are the revenue ranges for corticosteroids in the US idiopathic pulmonary-fibrosis-treatment market?

Corticosteroids generated revenue between $150.0 Million and $300.0 Million. Read More

How does the revenue from oral administration compare to intravenous administration in this market?

Oral administration generated revenue between $300.0 Million and $600.0 Million, while intravenous administration generated between $200.0 Million and $400.0 Million. Read More

What distribution channel had the highest revenue in the US idiopathic pulmonary-fibrosis-treatment market?

Retail pharmacies had revenue ranging from $250.0 Million to $500.0 Million. Read More

What is the revenue range for hospitals as an end user in the US idiopathic pulmonary-fibrosis-treatment market?

Hospitals generated revenue between $400.0 Million and $800.0 Million. Read More

Which key players are leading the US idiopathic pulmonary-fibrosis-treatment market?

Key players include Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Novartis, Galapagos, Pliant Therapeutics, FibroGen, and AstraZeneca. Read More

What is the revenue range for symptomatic treatment in the US idiopathic pulmonary-fibrosis-treatment market?

Symptomatic treatment generated revenue between $200.0 Million and $400.0 Million. Read More

US Idiopathic Pulmonary Fibrosis Treatment Market

Q: What is the expected CAGR for the US idiopathic pulmonary-fibrosis-treatment market during the forecast period 2025 - 2035?

The expected CAGR during this period is 6.73%. Read More

ID: MRFR/HC/13081-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Idiopathic Pulmonary Fibrosis Treatment Market Research Report: Size, Share, Trend Analysis By Drug Class (Antifibrotic Agents, Corticosteroids, Immunosuppressants, Symptomatic Treatment, Antibiotics), By Route of Administration (Oral, Intravenous, Subcutaneous, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics) and By End Users (Hospitals, Homecare, Ambulatory Surgical Centers) - Growth Outlook & Industry Forecast 2025 To 2035

US Idiopathic Pulmonary Fibrosis Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Drug Class (USD Million)
  1. 4.1.1 Antifibrotic Agents
  2. 4.1.2 Corticosteroids
  3. 4.1.3 Immunosuppressants
  4. 4.1.4 Symptomatic Treatment
  5. 4.1.5 Antibiotics
2. 4.2 Security, Access Control and Robotics, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Subcutaneous
  4. 4.2.4 Inhalation
3. 4.3 Security, Access Control and Robotics, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Online Pharmacies
  4. 4.3.4 Specialty Clinics
4. 4.4 Security, Access Control and Robotics, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Homecare
  3. 4.4.3 Ambulatory Surgical Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Boehringer Ingelheim (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Galapagos (BE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pliant Therapeutics (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 FibroGen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 (% SHARE)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Drug Class (USD Million, 2025-2035)

Antifibrotic Agents
Corticosteroids
Immunosuppressants
Symptomatic Treatment
Antibiotics

Security, Access Control and Robotics By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous
Inhalation

Security, Access Control and Robotics By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics

Security, Access Control and Robotics By End User (USD Million, 2025-2035)

Hospitals
Homecare
Ambulatory Surgical Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”